烟酸/laropiprant:一种新的脂质调节疗法

Future Prescriber Pub Date : 2009-02-26 DOI:10.1002/fps.44

Steve Chaplin MSc, MRPharmS, Marc Evans MRCP, MD

{"title":"烟酸/laropiprant:一种新的脂质调节疗法","authors":"Steve Chaplin MSc, MRPharmS, Marc Evans MRCP, MD","doi":"10.1002/fps.44","DOIUrl":null,"url":null,"abstract":"Cardiovascular disease (CVD) is a leading cause of death in the UK.1 Blood choleserol levels are a key risk factor for CVD, and can be modified by both drug treatment and lifestyle changes. In this article, Steve Chaplin considers the available clinical data on a new lipid-modifying therapy, a modified-release formulation of nicotinic acid and laropiprant; and Marc Evans comments on its potential contribution to reducing the risk of CVD. Copyright © 2009 John Wiley & Sons, Ltd.","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 1","pages":"20-23"},"PeriodicalIF":0.0000,"publicationDate":"2009-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.44","citationCount":"0","resultStr":"{\"title\":\"Nicotinic acid/laropiprant: a new lipid-modifying therapy\",\"authors\":\"Steve Chaplin MSc, MRPharmS, Marc Evans MRCP, MD\",\"doi\":\"10.1002/fps.44\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cardiovascular disease (CVD) is a leading cause of death in the UK.1 Blood choleserol levels are a key risk factor for CVD, and can be modified by both drug treatment and lifestyle changes. In this article, Steve Chaplin considers the available clinical data on a new lipid-modifying therapy, a modified-release formulation of nicotinic acid and laropiprant; and Marc Evans comments on its potential contribution to reducing the risk of CVD. Copyright © 2009 John Wiley & Sons, Ltd.\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"10 1\",\"pages\":\"20-23\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-02-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.44\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.44\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.44","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Nicotinic acid/laropiprant: a new lipid-modifying therapy

Cardiovascular disease (CVD) is a leading cause of death in the UK.¹ Blood choleserol levels are a key risk factor for CVD, and can be modified by both drug treatment and lifestyle changes. In this article, Steve Chaplin considers the available clinical data on a new lipid-modifying therapy, a modified-release formulation of nicotinic acid and laropiprant; and Marc Evans comments on its potential contribution to reducing the risk of CVD. Copyright © 2009 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量